BerGenBio ASA (BRRGF)

0.0250 0.0000 (0.00%) At close: 03:32PM EDT

BerGenBio ASA

Møllendalsbakken 9
Bergen 5009
Norway
47 55 96 11 59
https://www.bergenbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 18

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Martin Olin	Chief Executive Officer	874.04k	N/A	1969
Mr. Rune Skeie	Chief Financial Officer	232.92k	N/A	1973
Ms. Gayle M. Mills M.B.A	Chief Business Officer	N/A	N/A	1955
Ms. Cristina Oliva M.D.	Chief Medical Officer	31.18k	N/A	N/A
Graham Morell	Head of IR	N/A	N/A	N/A
Dr. Akil Jackson	Medical Director	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Corporate governance

BerGenBio ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.